Navigation Links
Selexis SA to Present at Biotech Showcase 2012
Date:1/5/2012

GENEVA, Switzerland, Jan. 5, 2012  /PRNewswire/ -- Selexis SA announced today the Company's president and CEO, Igor Fisch, Ph.D., will present at the Biotech Showcase 2012 Conference held in conjunction with the annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Dr. Fisch will present, "Translating Drug Discovery into Clinical Success: A Growth Investment" to prospective investors and corporate partners on Monday, January 9 at 11:00 AM in the Stockton Room at the Park 55 Wyndham.   The presentation will cover existing commercial offerings, the expansion of the SUREtechnology Platform™ and new market opportunities in drug discovery, next generation biologics and difficult to express proteins. 

"Biotech Showcase is an ideal opportunity for us to highlight our innovations and our applications of the SUREtechnology Platform™ supporting the biopharmaceutical industry's drug discovery efforts," said Dr. Fisch.  "Using Selexis' platform from discovery through manufacturing helps improve chances of clinical success while reducing development timelines and costs."

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins.  The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,300 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.  The Company anticipates three products manufactured from cell lines using t
'/>"/>

SOURCE Selexis SA
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Selexis Launches Biosimilar Cell Line Development Program
2. Irvine Scientific and Selexis to Announce Results of Successful Collaboration
3. Selexis SA Doubles Cell Line Development Laboratory Space in Geneva, Switzerland
4. Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome
5. Selexis SA to Partner and Exhibit at BIO 2011 in Washington DC
6. Selexis SA to Give Away Euro 25,000 SUREvariant Screening Service Project at BIO 2011
7. CSL Limited Signs Commercial License Agreement with Selexis SA
8. InterMune to Present at Canaccord Adams Conference
9. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
10. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
11. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... Orlando, Florida (PRWEB) March 31, 2015 ... announced the official relocation of their U.S. facilities and ... more than 25 years of experience, Cryos’ relocation is ... presence. , The move to Orlando was completed during ... with an official opening taking place on April 6. ...
(Date:3/30/2015)... 2015  Multiple new research abstracts suggest walnuts may ... factors. From their impact on colon cancer and certain ... both gut health and vascular health, the research findings ... understanding of walnuts, inner workings. Running March 28 through ... annual meeting attracts an international audience of over 14,000 ...
(Date:3/30/2015)... Md. , March 30, 2015 CASI ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a commercial focus on ... Food and Drug Administration (CFDA) has approved the Company,s ... in ovarian clear cell carcinoma (OCCC) patients for its ...
(Date:3/30/2015)... March 30, 2015 Immunocore ... drugs to treat cancer, viral infections and autoimmune ... John Bell , the Regius Professor of ... Office for the Strategic Coordination of Health Research, ...      (Photo: http://photos.prnewswire.com/prnh/20150330/736483 ) ...
Breaking Biology Technology:Cryos International Completes Groundbreaking Sperm Migration to Orlando, Florida 2New Findings Support the Benefits of Eating Walnuts on Overall Health 2New Findings Support the Benefits of Eating Walnuts on Overall Health 3New Findings Support the Benefits of Eating Walnuts on Overall Health 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5
... Aug. 19 /PRNewswire-Asia/ -- ... ... var shortURL = ""; ... so we need to grab the first one. for (var r in data.results) { first_result = ...
... LONDON, Aug. 19 Silence Therapeutics plc (AIM: SLN), ... note that its partner, Quark Pharmaceuticals, Inc. ("Quark"), has ... obtain an exclusive worldwide license to develop and commercialise ... Silence,s AtuRNAi technology. Quark is currently conducting ...
... THE WOODLANDS, Texas, Aug. 19 US Oncology, ... today that in less than two decades it has ... cancer therapies approved by the US Food and Drug ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20100517/DA06089LOGO ) ...
Cached Biology Technology:Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 2Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 3Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 4Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 5Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 6Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 7Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 8Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 9Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 10Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 11Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 12Silence Therapeutics' Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002 2US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research 2US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research 3US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research 4
(Date:3/24/2015)... WASHINGTON , March 24, 2015   NexID ... applications with critical security-authentication needs, today announced the beginning ... fake-finger-detection (FFD) solution. The company, based in ... announcement at the three-day Connect:ID Expo, which began here ... NexID said version 2.0 of its SDK boosts ...
(Date:3/23/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... television starting March 30 th . ... New York markets. ... about our new ad campaign following the recent initial shipment ...
(Date:3/19/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... this week on Washington DC,s Fox ... segment "The Next Great Thing", host Laura Evans ... and ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... of dinosaur unearthed in Mexico is giving scientists fresh insights ... an international research team led by scientists from the Utah ... To date, the dinosaur record from Mexico has been sparse, ... Natural History, Utahs designated natural history museum. The new ...
... HANOVER, N.H. Dartmouth College researchers and colleagues from ... the beginnings of complex life, i.e. vertebrates, to microRNA. ... regulate gene expression, are behind the origin of early ... to understanding the evolutionary origin of our own lineage, ...
... goal of Raphael Kopan, Ph.D., professor of molecular biology ... The moss plant (Physcomitrella patens) studied in the ... Professor and chair of the WUSTL biology department on ... Heres how. The gene presenilin in mammals ...
Cached Biology News:New dinosaur from Mexico offers insights into ancient life on West America 2New dinosaur from Mexico offers insights into ancient life on West America 3New dinosaur from Mexico offers insights into ancient life on West America 4New dinosaur from Mexico offers insights into ancient life on West America 5New dinosaur from Mexico offers insights into ancient life on West America 6Dartmouth researchers find the root of the evolutionary emergence of vertebrates 2Moss protein plays role in Alzheimer's disease 2Moss protein plays role in Alzheimer's disease 3Moss protein plays role in Alzheimer's disease 4
...
Human Cell Line Slides...
... Immunogen: Synthetic peptide derived from ... junctophilin-1. Specificity: Specific for the ... controls: mouse brain and skeletal muscle ... muscle tissues). Applications: Western blotting ...
Request Info...
Biology Products: